Clinical Trials Directory

Trials / Completed

CompletedNCT00089635

Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer

A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFr Levels of Immunohistochemistry Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
203 (actual)
Sponsor
Amgen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.

Conditions

Interventions

TypeNameDescription
DRUGPanitumumabAdministered by intravenous infusion

Timeline

Start date
2004-08-01
Primary completion
2007-01-01
Completion
2008-08-01
First posted
2004-08-11
Last updated
2022-11-07
Results posted
2013-12-05

Source: ClinicalTrials.gov record NCT00089635. Inclusion in this directory is not an endorsement.